biomimetic therapeutics inc. Resources | BNET
On GameSpot: Game analysts sound off on market crisis

BNET Industries

BioMimetic Therapeutics Inc. (BMTI) is in the Health Care Industry

Revenue
Dec 31 2007
$7.0M
Profit
Dec 31 2007
($24.5M)
Market Cap
Oct 09 2008
$128.5M

Latest News and Analysis

Additional Resources

  • page 1 of 1

View Related Content by Tag Close

  • Incorporated: 1999
  • CEO: Dr. Samuel E. Lynch D.M.D.,

BioMimetic Therapeutics develops and commercializes bio-active drug-device combination products for the healing of musculoskeletal injuries and diseases, including periodontal, orthopedic, spine and sports injury applications. Co.'s first drug-device combination product, GEM 21SŪ Growth-factor Enhanced Matrix, is approved by the FDA and marketed for the treatment of periodontal bone defects and gum tissue recession associated with periodontal disease. GEM 21S is a synthetic regeneration system that combines a tissue growth factor, recombinant human Platelet-Derived Growth Factor, with a synthetic bone matrix, beta-tricalcium phosphate.

Key Competitors

advertisement
BioMimetic Therapeutics Inc. Company Info

Board of Directors

Mr. Larry W. Papasan

Chairman

Mr. Chris Ehrlich

Mr. Charles W. Federico

Dr. Gary E. Friedlaender M.D.

Mr. James G. Murphy

Mr. Douglas Watson

Dr. Samuel E. Lynch D.M.D.,

Contact Information

389-A Nichol Mill Lane

Franklin, TN

http://www.biomimetics.com

615 844-1280

NAICS Code

Surgical and Medical Instrument Manufacturing: 339112

Brought to you by IBM

advertisement